Table 1.
Review of previous studies on SGLT2 inhibitors and LV function
| Author | SGLT2 inhibitor | Cohort | Imaging modality | Imaging findings |
|---|---|---|---|---|
| Verma S., et al. | Empagliflozin | 10 people with T2DM and CVD | TTE before and 3 months after | • Improved LV diastolic function according to early lateral e′ |
| • Reduced LV mass index | ||||
| • No difference in LV volumes and LV EF | ||||
| Matsutani D., et al. | Canagliflozin | 37 people with T2DM and ≥2 CVD risk factors or CVD | TTE before and 3 months after | • Improved LV diastolic function according to the E/e′ ratio |
| • Reduced LV mass index | ||||
| • No difference in LV diameters, LV EF, and left atrial diameter | ||||
| Soga F., et al. | Dapagliflozin | 53 people with T2DM and stable HFrEF or HFpEF | TTE before and 6 months after | • Improved LV diastolic function according to the E/e′ ratio |
| • Reduced LV mass index and left atrial volume index | ||||
| • No difference in LV volumes | ||||
| • Improved LV EF | ||||
| Sakai T., et al.a | Empagliflozin | 59 people with T2DM and HFpEF | TTE before and 3 months after | • Improved LV diastolic function according to the E/A and E/e′ ratios |
| Luseogliflozin | 63 people with T2DM and HFpEF | |||
| Tofogliflozin | 62 people with T2DM and HFpEF | |||
| Verma S., et al.a | Empagliflozin vs. placebo | 97 people with T2DM and CVD (49 drug and 48 placebo) | Cardiac MRI before and 6 months after | • Improved LV mass index |
| • No difference in LV EF and LV end‐systolic volume | ||||
| Cohen N., et al. | Empagliflozin vs. placebo | 25 people with T2DM (17 drug and 8 placebo) | Cardiac MRI before and 6 months after | • Reduced LV end‐diastolic volume |
| • No difference in LV mass, LV EF, atrial volumes, and markers of cardiac fibrosis |
A, mitral peak A‐wave velocity; CVD, cardiovascular disease; E, mitral peak E‐wave velocity; e′, early annular tissue Doppler velocity; EF, ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; MRI, magnetic resonance imaging; SGLT2, sodium‐glucose cotransporter 2; T2DM, type 2 diabetes mellitus; TTE, transthoracic echocardiography.
a
Preliminary data obtained from abstract or conference presentation.